Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Intranasal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    280 result(s) found for: Intranasal. Displaying page 8 of 14.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2018-002474-52 Sponsor Protocol Number: AM-125-CL-18-01 Start Date*: 2019-04-01
    Sponsor Name:Auris Medical AG
    Full Title: Multicenter randomized controlled phase 2 trial to evaluate AM-125 in the treatment of acute peripheral vertigo following neurosurgery (TRAVERS)
    Medical condition: Treatment of acute peripheral vertigo
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10059614 Vestibular vertigo LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005161-20 Sponsor Protocol Number: SCC01 Start Date*: 2012-02-14
    Sponsor Name:University College Dublin Clinical Research Centre
    Full Title: A Randomised Controlled Double-Blind Trial of Intranasal Fentanyl versus Intravenous Morphine in the Emergency Department Treatment of Severe Painful Sickle Cell Crises in Children
    Medical condition: Severe Painful Sickle Cell Disease Crises in Children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003019-39 Sponsor Protocol Number: Start Date*: Information not available in EudraCT
    Sponsor Name:
    Full Title: Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 study
    Medical condition: Children aged 2-18 years (inclusive), some of whom will have asthma and/or food allergies.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10001738 Allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022113-25 Sponsor Protocol Number: RVH002 Start Date*: 2010-10-20
    Sponsor Name:RespiVert Ltd
    Full Title: A two day, randomised, single blind, parallel group trial of repeat doses of intranasal RV568 in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)
    Medical condition: Seasonal Allergic Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001910-40 Sponsor Protocol Number: 0305070107 Start Date*: 2020-06-09
    Sponsor Name:Radboud University
    Full Title: Combining emotion recognition training with oxytocin administration: A psychobiological approach
    Medical condition: We examine whether oxytocin administration can improve the effectiveness of emotion recognition training compared to placebo in residential youth with antisocial behavior
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006678-12 Sponsor Protocol Number: 05ct149fe Start Date*: 2007-06-29
    Sponsor Name:Haupt Pharma Wolfratshausen GmbH
    Full Title: Nasal Transmucosal Fentanyl Citrate (NTFC) versus Oral Morphine Sulphate (OMS): A double-blind, double dummy, randomised, multi-centre, comparative cross-over study for the treatment of breakthroug...
    Medical condition: Cancer-related breakthrough pain
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064556 Breakthrough pain LLT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000367-16 Sponsor Protocol Number: 0305070106 Start Date*: 2017-03-23
    Sponsor Name:Radboud University Nijmegen
    Full Title: The effect of oxytocin administration on empathy and emotion recognition in healthy and antisocial adolescents
    Medical condition: We examine the effect of oxytocin administration on empathy and emotion recognition in healthy adolescents and adolescents with antisocial behavior and history of severe psychological trauma
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004922-16 Sponsor Protocol Number: P06333 Start Date*: 2015-02-24
    Sponsor Name:Corporation Schering-Plough K.K.
    Full Title: A study of long-term (12-24 weeks) administration of mometasone furoate nasal spray in pediatric subjects with perennial allergic rhinitis (Protocol No. P06333)
    Medical condition: Perennial Allergic Rhinitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-000848-17 Sponsor Protocol Number: MI-CP129 Start Date*: 2017-12-12
    Sponsor Name:MedImmune
    Full Title: A Phase 2, Open-Label, Single Arm Trial to Evaluate the Shedding and Safety of CAIV-T Administered to Children 6 to less than 60 Months of Age
    Medical condition: The prevention of Influenza Virus in infants and young children ages 6 to < 60 months of age.
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019892-31 Sponsor Protocol Number: 65759682 Start Date*: 2011-06-15
    Sponsor Name:Lightlake Sinclair Oy
    Full Title: Hoitotutkimus BED-syömishäiriöstä ja sen taustatekijöistä
    Medical condition: Binge Eating-Disorder, BED on ylipainoisilla esiintyvä syömishäiriö, jolle on luonteenomaista ahminta. Tutkimuksessa selvitetään nasaalisen (nenän kautta annosteltavan) naloksonilääkkeen tehoa BES ...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10004716 Binge eating PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023815-33 Sponsor Protocol Number: GHB_CSP_CL_00008_03 Start Date*: 2011-01-05
    Sponsor Name:AVIR Green Hills Biotechnology Research Development Trade AG
    Full Title: Randomised, double-blind, placebo-controlled, phase I/II study of single dose GHB16L2 trivalent influenza vaccine in healthy adults
    Medical condition: The intended indication for the IMP GHB16L2 is prevention of influenza A (H1N1, H3N2) and B contained in the vaccine.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002872-41 Sponsor Protocol Number: ELR100710 Start Date*: 2005-10-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Study to Validate Key Therapeutic Targets and Biomarkers during Allergen Exposure in Subjects with Allergic Rhinitis
    Medical condition: Seasonal allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005366-38 Sponsor Protocol Number: 2011-112 Start Date*: 2012-02-26
    Sponsor Name:Ambulance Service, Stockholm City Council
    Full Title: Treatment of pain in Ambulance Services with Sufenta® nasally compared to Morfin® intravenously.
    Medical condition: Severe pain treated in ambulance service.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000849-50 Sponsor Protocol Number: MI-CP114 Start Date*: 2017-12-12
    Sponsor Name:MedImmune
    Full Title: A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of...
    Medical condition: The prevention of Influenza Virus in Immunocompromised children ages 5 through 17 years of age.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-001621-29 Sponsor Protocol Number: 80804002 Start Date*: 2009-05-05
    Sponsor Name:Faculty of Medicine Carl Gustav Carus, University of Technology, Dresden
    Full Title: Pre-POINT (Primary Oral INsulin Trial) study A dose finding safety and immune efficacy study for primary mucosal insulin therapy in islet autoantibody negative children at high genetic risk for ty...
    Medical condition: pre-type 1 diabetes (islet autoimmunity in non-diabetic relatives of subjects with type 1 diabetes)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006531-26 Sponsor Protocol Number: 001-738 Start Date*: 2023-05-14
    Sponsor Name:Oslo University Hospital
    Full Title: A randomized, placebo-controlled, double-blind, 2-period cross-over study in youth with autism spectrum disorders evaluating social and repetitive behaviors after four weeks of twice daily-doses of...
    Medical condition: Autism spectrum disorders
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000156-11 Sponsor Protocol Number: S65914 Start Date*: 2022-02-25
    Sponsor Name:KU Leuven
    Full Title: Oxytocin and the development of attachment: Looking beyond the expected?
    Medical condition: General healthy population children (ages 8 - 13 years old).
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001280-22 Sponsor Protocol Number: 23-3-2018 Start Date*: 2018-08-22
    Sponsor Name:Merja Kokki
    Full Title: -
    Medical condition: -
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10036236 Postoperative pain relief LLT
    21.1 100000004865 10048935 Open heart surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001088-11 Sponsor Protocol Number: s56489 Start Date*: 2014-07-29
    Sponsor Name:MEDA
    Full Title: Academic study on the effects of MP 29-02 nasal spray on inflammatory mediators in allergic rhinitis
    Medical condition: Allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004925-42 Sponsor Protocol Number: P04824 Start Date*: 2015-04-13
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis
    Medical condition: Acute Bacterial Sinusitis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 25 06:02:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA